A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Saracatinib (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- 18 Nov 2016 Planned number of patients changed from 20 to 90.
- 18 Nov 2016 Planned End Date changed from 1 Oct 2019 to 1 Oct 2021.
- 07 Jan 2016 New trial record